Published in Mol Cancer Ther on August 01, 2008
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab (2010) 2.53
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature (2012) 1.68
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
New frontiers in androgen biosynthesis and metabolism. Curr Opin Endocrinol Diabetes Obes (2010) 1.19
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res (2013) 1.13
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem (2011) 1.10
Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol (2014) 1.08
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res (2014) 1.00
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget (2015) 0.98
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer (2010) 0.97
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab (2011) 0.96
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2011) 0.93
New hormonal therapies for castration-resistant prostate cancer. Endocrinol Metab Clin North Am (2011) 0.90
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol (2012) 0.89
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci (2013) 0.88
HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia (2009) 0.87
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl (2014) 0.86
Androgen biosynthesis in castration-resistant prostate cancer. Endocr Relat Cancer (2014) 0.85
Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther (2013) 0.85
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol (2014) 0.84
CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids (2015) 0.84
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol (2008) 0.84
Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer (2013) 0.83
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin Pharmacol Ther (2015) 0.83
Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab Dispos (2010) 0.82
Concept and viability of androgen annihilation for advanced prostate cancer. Cancer (2014) 0.82
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther (2014) 0.82
Serially heterotransplanted human prostate tumours as an experimental model. J Cell Mol Med (2009) 0.80
Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective. Asian J Androl (2012) 0.79
New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer (2011) 0.79
Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. World J Urol (2011) 0.78
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2016) 0.77
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer (2016) 0.77
Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother (2015) 0.77
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg (2010) 0.76
Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate. ACS Med Chem Lett (2016) 0.75
Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics. Comput Struct Biotechnol J (2015) 0.75
Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Des Devel Ther (2016) 0.75
Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report. Clin Genitourin Cancer (2014) 0.75
Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion. FEBS J (2016) 0.75
Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1). Expert Opin Ther Pat (2015) 0.75
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. J Clin Invest (2017) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem (1968) 3.54
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (2001) 3.06
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer (1999) 2.34
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem (2005) 1.80
Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res (1996) 1.78
Androgen receptor mutations in prostate cancer. Cancer Res (2000) 1.74
CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther (2006) 1.71
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol (1997) 1.63
Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol (2004) 1.62
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A (1998) 1.45
Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol (2006) 1.33
Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res (2005) 1.28
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics (2002) 1.26
Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol (1983) 1.24
A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res (2007) 1.22
Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer (2002) 1.13
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res (2000) 1.13
Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis (2007) 1.02
Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol Cancer Ther (2003) 0.98
Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine (1999) 0.98
Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. J Med Chem (1998) 0.92
Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Res (1996) 0.89
Mechanism of androgen-receptor augmentation. Analysis of receptor synthesis and degradation by the density-shift technique. J Biol Chem (1985) 0.88
Degradation and beyond: control of androgen receptor activity by the proteasome system. Cell Mol Biol Lett (2006) 0.87
Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer. Curr Pharm Des (1999) 0.87
Inhibition of CYP 17, a new strategy for the treatment of prostate cancer. Arch Pharm (Weinheim) (2002) 0.87
Physiologic basis of endocrine therapy for prostatic cancer. Urol Clin North Am (1991) 0.86
Cytochrome P-450 C21scc: one enzyme with two actions: hydroxylase and lyase. J Steroid Biochem Mol Biol (1991) 0.85
Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids (1995) 0.83
Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer (1999) 0.82
Inhibition of p450 17 as a new strategy for the treatment of prostate cancer. Curr Med Chem (2005) 0.81
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. J Steroid Biochem Mol Biol (2004) 0.81
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
Age-associated DNA methylation in pediatric populations. Genome Res (2012) 2.53
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids (2006) 1.89
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res (2005) 1.84
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem (2005) 1.80
Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell (2009) 1.77
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res (2007) 1.57
The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem (2007) 1.55
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget (2014) 1.51
Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res (2007) 1.51
Living donor vs. deceased donor liver transplantation for patients with hepatitis C virus-related diseases. J Hepatol (2012) 1.44
PGC1α promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res (2011) 1.43
Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem (2006) 1.41
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother (2004) 1.41
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res (2012) 1.41
Tetracarboxylate-based Co(II), Ni(II) and Cu(II) three-dimensional coordination polymers: syntheses, structures and magnetic properties. Dalton Trans (2010) 1.39
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res (2009) 1.39
Stopping treatment can reverse acquired resistance to letrozole. Cancer Res (2008) 1.39
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res (2009) 1.38
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem (2005) 1.33
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat Med (2003) 1.30
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics (2002) 1.26
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res (2005) 1.23
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood (2010) 1.23
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res (2006) 1.22
Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J Biol Chem (2011) 1.21
Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res (2006) 1.20
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem (2007) 1.20
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res (2007) 1.19
Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl (2012) 1.18
Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem (2013) 1.18
The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate (2004) 1.15
Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat (2010) 1.14
Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int J Clin Exp Pathol (2013) 1.13
1H and 13C NMR assignments for two anthraquinones and two xanthones from the mangrove fungus (ZSUH-36). Magn Reson Chem (2007) 1.12
Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene (2004) 1.12
Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res (2010) 1.11
P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer (2006) 1.11
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
"Default" generation of neonatal regulatory T cells. J Immunol (2010) 1.10
Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res (2011) 1.09
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem (2007) 1.07
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol (2006) 1.06
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res (2009) 1.05
Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation. Arthritis Rheum (2013) 1.05
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Stat Med (2005) 1.03
Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorg Med Chem (2008) 1.03
Array-based assay detects genome-wide 5-mC and 5-hmC in the brains of humans, non-human primates, and mice. BMC Genomics (2014) 1.03
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther (2012) 1.03
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem (2015) 1.02
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res (2014) 1.01
The anti-ulcer activities of bisabolangelone from Angelica polymorpha. J Ethnopharmacol (2009) 1.01
A luminescent mixed-lanthanide metal-organic framework thermometer. J Am Chem Soc (2012) 1.01
Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl (2012) 1.00
Down-regulation of microRNA-26a promotes mouse hepatocyte proliferation during liver regeneration. PLoS One (2012) 1.00
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Oncologist (2011) 1.00
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther (2008) 0.99
17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther (2008) 0.99
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist (2008) 0.99
Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Cancer Res (2006) 0.98
Study of flow-induced hemolysis using novel Couette-type blood-shearing devices. Artif Organs (2011) 0.98
The development and function of follicular helper T cells in immune responses. Cell Mol Immunol (2012) 0.98
Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation (2012) 0.98
Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to the FMR1 locus. BMC Med Genet (2013) 0.97
Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol (2003) 0.96
CDC25A functions as a novel Ar corepressor in prostate cancer cells. J Mol Biol (2008) 0.94
Testosterone signaling in T cells and macrophages. Steroids (2002) 0.94
Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage. J Biol Chem (2004) 0.93
Autophagy inhibition synergistically enhances anticancer efficacy of RAMBA, VN/12-1 in SKBR-3 cells, and tumor xenografts. Mol Cancer Ther (2012) 0.92
Diazoxide prevents diabetes through inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax rate and p38-beta mitogen-activated protein kinase. Endocrinology (2006) 0.91
Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. Transplantation (2014) 0.90
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res (2013) 0.90
Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS One (2011) 0.89
Synthesis of a new Ni-phenanthroline complex and its application as an electrochemical probe for detection of nucleic acid. Biosens Bioelectron (2011) 0.89